Bristol-Pfizer's blood thinner Eliquis wins FDA approval

Bristol-Myers Squibb and Pfizer's Eliquis, or apixaban, has been approved by the FDA to reduce the risk of strokes and blood clots for people with atrial fibrillation. The anticoagulant, however, should not be given to patients with artificial heart valves or those with atrial fibrillation due to heart valve problems, the FDA said. Eliquis, which has been approved in Europe, is seen has having the potential to become a blockbuster.

View Full Article in:

New York Times (tiered subscription model), The · USA Today

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC